Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH1R132H mutation increases radiotherapy efficacy and a 4-gene radiotherapy-related signature of WHO grade 4 gliomas.

Scientific reports - 11 Nov 2023

Han Xuetao, Zhou Huandi, Sun Wei, Hou Liubing, Wang Yanqiang, Wang Hong, Lv Zhongqiang, Xue Xiaoying

Abstract excerpt

The prognosis for the WHO grade 4 IDH-mutant astrocytoma is better than IDH-wildtype glioblastoma (GBM) patients. The purpose of this study is to explore the potential mechanism of how IDH1 mutation can increase the efficacy of radiotherapy and to establish a risk-score model to predict the efficacy of radiotherapy in WHO grade 4 gliomas. First, we conducted experimental study on the effect of IDH1R132H mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Calmodulin-Binding Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioblastoma

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Prognosis

Share to World Health Organization

Source

Open in PubMed Open full text

Identifiers

PMID: 37952042
DOI: 10.1038/s41598-023-46335-1
PMCID: PMC10640646

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH1R132H mutation increases radiotherapy efficacy and a 4-gene radiotherapy-related signature of WHO grade 4 gliomas.PMID 37952042Read ↗

Tumor Mutational Burden Predicts Survival In Patients With Low Grade Gliomas Expressing Mutated IDH1Semantic proximity Read ↗

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.Semantic proximity Read ↗

The prognosis of gliomas with different molecular subtypes in the era of intensity-modulated radiation therapy (IMRT).Semantic proximity Read ↗

Integrating Radiosensitivity Gene Signature Improves Glioma Outcome and Radiotherapy Response PredictionSemantic proximity Read ↗

Molecular classification of IDH-mutant glioblastomas based on gene expression profilesSemantic proximity Read ↗

IDH1 mutation diminishes aggressive phenotype in glioma stem cells.Semantic proximity Read ↗

IDH1 <sup>R132H</sup> acts as a tumor suppressor in glioma via epigenetic upregulation of the DNA damage responseSemantic proximity Read ↗

Unraveling the tumor-promoting role of wildtype Isocitrate dehydrogenase 1 (IDH1) in human gliomasSemantic proximity Read ↗

IDH1 mutation activates mTOR signaling pathway, promotes cell proliferation and invasion in glioma cells.Semantic proximity Read ↗

IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.Semantic proximity Read ↗

IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.Semantic proximity Read ↗

Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.